Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1)

Creators: Arcelli A.; Buwenge M.; Macchia G.; Bertini F.; Guido A.; Deodato F.; Cilla S.; Scotti V.; Rosetto M. E.; Djan I.; Parisi S.; Mattiucci G. C.; Cellini F.; Fiore M.; Bonomo P.; Belgioia L.; Niespolo R. M.; Gabriele P.; Di Marco M.; Simoni N.; Mazzarotto R.; Morganti A. G.

Others:: Arcelli, A.; Buwenge, M.; Macchia, G.; Bertini, F.; Guido, A.; Deodato, F.; Cilla, S.; Scotti, V.; Rosetto, M. E.; Djan, I.; Parisi, S.; Mattiucci, G. C.; Cellini, F.; Fiore, M.; Bonomo, P.; Belgioia, L.; Niespolo, R. M.; Gabriele, P.; Di Marco, M.; Simoni, N.; Mazzarotto, R.; Morganti, A. G.

Description

Conventionally fractionated chemoradiation (CRT) or chemotherapy (CHT) are considered as standard options in locally advanced pancreatic cancer (LAPC) while stereotactic body radiotherapy (SBRT) is an emerging treatment in this setting. The aim of this study was to compare two cohorts of LAPC patients treated with SBRT ± CHT vs CRT ± CHT in terms of local control (LC), distant metastases-free survival (DMFS), progression-free survival (PFS), overall survival (OS), and toxicity. Eighty patients were included. Patients in the two cohorts were matched according to: age ≤/>65 years, tumor diameter (two cut-offs:

Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1)

Description

Additional details